Relevant bibliographies by topics / Bioresponsive

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Bioresponsive'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bioresponsive.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bioresponsive"

1

Ulijn, Rein V., Nurguse Bibi, Vineetha Jayawarna, Paul D. Thornton, Simon J. Todd, Robert J. Mart, Andrew M. Smith, and Julie E. Gough. "Bioresponsive hydrogels." Materials Today 10, no. 4 (April 2007): 40–48. http://dx.doi.org/10.1016/s1369-7021(07)70049-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wilson, A. Nolan, and Anthony Guiseppi-Elie. "Bioresponsive Hydrogels." Advanced Healthcare Materials 2, no. 4 (December 10, 2012): 520–32. http://dx.doi.org/10.1002/adhm.201200332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Jongseong, Satish Nayak, and L. Andrew Lyon. "Bioresponsive Hydrogel Microlenses." Journal of the American Chemical Society 127, no. 26 (July 2005): 9588–92. http://dx.doi.org/10.1021/ja0519076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yu, Jicheng, Yuqi Zhang, Anna R. Kahkoska, and Zhen Gu. "Bioresponsive transcutaneous patches." Current Opinion in Biotechnology 48 (December 2017): 28–32. http://dx.doi.org/10.1016/j.copbio.2017.03.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trotta, Francesco, Fabrizio Caldera, Chiara Dianzani, Monica Argenziano, Giuseppina Barrera, and Roberta Cavalli. "Glutathione Bioresponsive Cyclodextrin Nanosponges." ChemPlusChem 81, no. 5 (December 15, 2015): 439–43. http://dx.doi.org/10.1002/cplu.201500531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Trotta, Francesco, Fabrizio Caldera, Chiara Dianzani, Monica Argenziano, Giuseppina Barrera, and Roberta Cavalli. "Glutathione Bioresponsive Cyclodextrin Nanosponges." ChemPlusChem 81, no. 5 (March 15, 2016): 434. http://dx.doi.org/10.1002/cplu.201600105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Meng, Benqing Zhou, Lu Wang, Feifan Zhou, Nataliya Smith, Debra Saunders, Rheal A. Towner, Jun Song, Junle Qu, and Wei R. Chen. "Biodegradable pH-responsive amorphous calcium carbonate nanoparticles as immunoadjuvants for multimodal imaging and enhanced photoimmunotherapy." Journal of Materials Chemistry B 8, no. 36 (2020): 8261–70. http://dx.doi.org/10.1039/d0tb01453b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Xin, Xiaoqian, Zhongxia Zhang, Xican Zhang, Jian Chen, Xi Lin, Pinghua Sun, and Xiaowen Liu. "Bioresponsive nanomedicines based on dynamic covalent bonds." Nanoscale 13, no. 27 (2021): 11712–33. http://dx.doi.org/10.1039/d1nr02836g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

You, Jin-Oh, Dariela Almeda, George JC Ye, and Debra T. Auguste. "Bioresponsive matrices in drug delivery." Journal of Biological Engineering 4, no. 1 (2010): 15. http://dx.doi.org/10.1186/1754-1611-4-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Heffern, Marie C., Lauren M. Matosziuk, and Thomas J. Meade. "Lanthanide Probes for Bioresponsive Imaging." Chemical Reviews 114, no. 8 (December 13, 2013): 4496–539. http://dx.doi.org/10.1021/cr400477t.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bioresponsive"

1

Deacon, Samuel Philip Edward. "Bioresponsive polymer therapeutics containing coiled-coil motifs." Thesis, Cardiff University, 2009. http://orca.cf.ac.uk/55819/.

Full text
Abstract:
Polyethyleneglycol (PEG) conjugates of peptides, proteins and an aptamer are in routine clinical use as first generation nanomedicines. Here a new family of polymer therapeutics based on PEG conjugates containing a coiled-coil peptide motif as a molecular switch are proposed. The coiled-coil motif is adopted by many naturally occurring proteins/peptides, including transcription factors key to cancer progression (E2F1/AP-1) and Ebola virus proteins (VP35/GP2). These were chosen as the first targets, however there is potentially a much wider role for this novel family of therapeutics. First studies selected coiled-coil motif peptide sequences (using computational prediction software and published literature) that were then synthesised using a solid phase approach, purified and characterised. To facilitate subsequent PEGylation, peptides were engineered to include an N-terminal cysteine residue. mPEG-maleimide (-5,500 g mol 1) was then conjugated site-specifically via the cysteine thiol. A purification method optimised using cation-exchange chromatography enabled the removal of both unreacted mPEG-maleimide and free peptide purity was > 95 % for each conjugate. Proof of concept was obtained with mPEG-FosWc, which was designed to inhibit coiled-coil heterodimerisation of native c-Jun and c-Fos proteins (AP-1). 1H, 15N HSQC spectroscopy confirmed target hybridisation of heterodimeric coiled-coils FosWc : c-Jun and mPEG-FosWc : c-Jun. In addition, both NMR and CD spectroscopy showed that both heterodimers adopted very similar structures under physiological conditions, irrespective of the presence or absence of PEG. Further studies using fluorescently labelled conjugates investigated cellular uptake in MCF-7 cells, and biological activity was assessed using the MTT assay with and without the use of a cationic transfection reagent. These studies demonstrate the potential of mPEG-coiled-coil motifs as therapeutic agents. However, demonstrating reproducible biological activity was not possible with the intracellular targets. Investigating the biological activity of the conjugates designed to target the extracellular Ebola virus fusion proteins remains an exciting prospect.
APA, Harvard, Vancouver, ISO, and other styles
2

Wilson, Andrew Nolan. "Drug delivery with feedback control in bioresponsive hydrogels." Thesis, Clemson University, 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3624014.

Full text
Abstract:

Bioresponsive hydrogels are emerging with technological significance in targeted drug delivery, biosensors and regenerative medicine. The design challenge is to effectively link the conferred biospecificity with an engineered response tailored to the needs of a particular application. Moreover, the fundamental phenomena governing the response must support an appropriate dynamic range, limit of detection and the potential for feedback control. The design of these systems is inherently complicated due to the high interdependency of the governing phenomena that guide sensing, transduction and actuation of the hydrogel. The objective of the dissertation is to review the current state of bioresponsive hydrogel technology and introduce a method of extending the technology through integrated control loops; explore fundamental phenomena which affect ion transport within biomimetic hydrogels; and investigate, via in silico studies, the fundamental design parameters for the implementation of a feedback control loop within a bioresponsive hydrogel.

In one study, effects of valence number, temperature and polymer swelling on release profiles of monovalent potassium and divalent calcium ions elucidates mechanistic characteristics of polymer interactions with charged species. For comparison, ions were loaded during hydrogel formulation or loaded by partitioning following construct synthesis. Using the Korsmeyer-Peppas release model, the diffusional exponents were found to be Fickian for pre- and post-loaded potassium ions while preloaded calcium ions followed an anomalous behavior and postloaded calcium ions followed Case II behavior. Results indicate divalent cations interact through cation-polyelectrolyte anion complexation while monovalent ions do not interact with the polymer. Temperature dependence of potassium ion release was shown to follow an Arrhenius relation and calcium ion release was temperature independent.

In another study, data generated from the previous Chymotrypsin system is used to build and validate a finite element model. The model provides insight into key engineering parameters for the design of an enzymatically actuated, feedback controlled release. A drug delivery platform comprising a biocompatible, bioresponsive hydrogel and possessing a covalently tethered peptide-inhibitor conjugate was engineered to achieve stasis, via a closed control loop, of the external biochemical activity of the actuating enzyme. The FEM model was used to investigate the release of a competitive protease inhibitor, MAG283, via cleavage of Acetyl-Pro-Leu-Gly|Leu-MAG-283 by MMP-9 in order to achieve targeted homeostasis of MMP-9 activity, a goal for the treatment of chronic wound pathophysiology. It was found the key engineering parameters for the delivery device are the radii of the hydrogel microspheres and the concentration of the peptide-inhibitor conjugate loaded into the hydrogel.

Homeostatic drug delivery, where the focus turns away from the drug release rate and turns towards achieving targeted control of biochemical activity within a biochemical pathway, is an emerging approach in drug delivery methodologies for which the potential has not yet been fully realized. By understanding mechanistic phenomena and key engineering parameters for design, advancements in bioresponsive hydrogels will continue to produce novel technologies in biomedical applications.

APA, Harvard, Vancouver, ISO, and other styles
3

Bolarinwa, Aminat. "The formulation of a bioresponsive ceramic bone replacement." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/1073/.

Full text
Abstract:
The long-term stability and brittle nature of ceramic bone replacements in physiological conditions makes them prone to mechanical failure. These problems have led to the development of bioresorbable bone replacement materials. Bioresorbable biomaterials are expected to degrade at a rate which is proportional to the rate of formation of new bone tissue. In the majority of cases, however, resorption is driven by simple dissolution and so it is difficult to ensure an appropriate degradation rate for all patients. This thesis seeks to develop a material that can degrade in response to the bone formation process, thus linking implant resorption to tissue formation. We have shown that this can be achieved by linking implant resorption to a biological stimulus, such as the enzyme alkaline phosphatase (ALP), which is found on the surface of bone forming cells (osteoblasts). ALP causes bone mineralisation by removing the pyrophosphate (P\(_2\)O\(_7\)\(^4\)\(^-\)) ion, a known inhibitor to calcium phosphate formation. By removing the P\(_2\)O\(_7\)\(^4\)\(^-\) P2O74- ions from solution the dissolution of calcium pyrophosphate ((Ca\(_2\)P\(_2\)O\(_7\)\(^4\)\(^-\)) crystals were accelerated in accordance with Le Chetalier's principle. We demonstrated that for this accelerated dissolution to occur, the ALP did not require access to the crystal surface. This is contrary to previous work which suggested that CPPD dissolution occurred as a result of ALP cleaving the crystal surface. Bulk (Ca\(_2\)P\(_2\)O\(_7\)\ ceramics were successfully produced by sintering brushite cement at temperatures ≥ 400°C, the dissolution of which could accelerated in the presence of ALP but was heavily dependent on material specific surface area. The process of sintering limits the possibility of producing biomaterials of complex morphology; therefore the final part of this thesis involved the fabrication of ((Ca\(_2\)P\(_2\)O\(_7\) ceramic using stereolithography.
APA, Harvard, Vancouver, ISO, and other styles
4

Philipp, Alexander. "Delivery of siRNA with bioresponsive cationic polymer-based carriers." Diss., lmu, 2010. http://d-nb.info/1000906132/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hopkinson, Devan. "Bioresponsive liposomes to target drug release in alveolar macrophages." Thesis, University of Manchester, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.713597.

Full text
Abstract:
Tuberculosis is one of the most prevalent infectious diseases globally due to the successful survival mechanisms displayed by Mycobacterium tuberculosis (Mtb). Mtb primarily infects alveolar macrophages (AMs) and is able to live intracellularly for extended periods of time due to a number of virulence factors which inhibit the antibacterial mechanisms of the AMs. This aspect of the Mtb life cycle means TB treatments suffer from poor bioavailability and efficacy. Additionally, the rise in resistant strains of Mtb means the use of higher doses and the use of alternative second and third line drugs which increase the risk of systemic toxicity. Drug encapsulation is a novel approach that can provide more favourable drug pharmacokinetics and pharmacodynamics. The aim of this project was to develop a liposomal drug delivery system to target Mtb infected alveolar macrophages. The system involved the encapsulation of two drugs; the antibiotic gatifloxacin (GFLX) and Mtb virulence factor inhibitor CV7. The hypothesis was that the two different antibacterial mechanisms would work in synergy and increase the efficacy of the treatment. AM targeting and receptor-mediated endocytic uptake was encouraged by the presence of a ligand attached to the surface of the liposome. Furthermore a pH-sensitive release mechanism was to be incorporated into the liposome to encourage the release of the encapsulated drugs in the vicinity of the intracellular bacteria. The intention was to produce a drug delivery system to enable a TB therapy regime of fewer, lower doses to increase compliance and reduce systemic toxicity by increasing efficacy through improved bioavailability. GFLX was successfully encapsulated using a weak base active loading method. To establish encapsulation efficiency, a homogeneous fluorescence assay able to quantify intra- and extra-liposomal gatifloxacin simultaneously was developed. pH-sensitive release of the payload could be achieved using a pH-sensitive peptide with a novel design based on chimeric structure, namely P3. CV7 was successfully encapsulated using a weak acid active loading method. CV7 liposomes were able to be functionalised by the incorporation of a mannose ligand on the surface of the liposome. An inhibition assay using the target enzyme of CV7, MptpB, was optimised to assess efficacy of liposomally encapsulated and released CV7. Flow cytometry and confocal microscopy studies confirmed that the liposomal formulations were internalised by the target macrophage cell line, J774a.1. Mannose liposomes conveyed superior uptake kinetics. Further confocal microscopy showed that after internalisation the liposomes entered the endolysosomal pathway and colocalised with BCG. A BCG-macrophage infection model was used to determine the intracellular efficacy of the liposomal formulations. Encapsulated CV7 displayed increased efficacy over free CV7, while encapsulation in functionalised liposomes showed better efficacy still. The encapsulation of GFLX did not increase the efficacy of GFLX and synergy between the two drugs was not achieved. In conclusion, the liposomal encapsulation of CV7 increased uptake of the drug by the target cell line and facilitated colocalisation of the drug with the target pathogen thereby increasing efficacy. Such a formulation could potentially increase bioavailability and efficacy in vivo for a more tolerable TB therapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Ashrafi, Koorosh. "Novel bioresponsive drug eluting microspheres to enhance chemoembolisation therapy." Thesis, University of Brighton, 2014. https://research.brighton.ac.uk/en/studentTheses/d72e0cce-8b99-4659-9b8d-c0e5a48da701.

Full text
Abstract:
Drug eluting beads (DEB) are employed in the treatment of solid hypervascularised malignant tumours by a method called trans-arterial chemoembolisation (TACE). When the microcirculation to a tumour is blocked, oxygen levels decrease to critically low levels causing the tumour to become hypoxic. Hypoxic tumours are known to be chemoresistant and send out growth factor signals leading to angiogenesis and metastasis of tumour cells to other parts of the body. Commercially available DEB are unable to respond to the conditions of hypoxia and will continue to release drug at a constant rate via ionic exchange through the hydrogel. It is therefore recognised that an avenue for improvement would be the development of novel bioresponsive DEB that are able to react to the conditions of hypoxia to overcome chemoresistance associated with the tumour cells.
APA, Harvard, Vancouver, ISO, and other styles
7

Gilbert, Helena Rosalind Petra. "Bioresponsive polymer-protection conjugates as a unimolecular drug delivery system." Thesis, Cardiff University, 2007. http://orca.cf.ac.uk/55685/.

Full text
Abstract:
PEGylation has become very popular for the generation of nanomedicines with improved protein delivery properties, despite its lack of biodegradability. Researchers usually try to maximise retained protein activity during PEGylation. However, this proof of principle study aimed to create an inactive peptide or enzyme product, using a biodegradable polymer, that would elicit minimal activity/non-specific toxicity on administration. Following triggered site-specific degradation of the polymer, the hypothesis was that protein activity could be slowly regenerated in the general circulation or localised to a specific target site. Model conjugates were synthesised by coupling dextrin degraded by amylase to trypsin and melanocyte stimulating hormone MSH, to test this concept and targeted delivery for both an enzyme and a receptor-binding ligand. Hyaluronic acid HA degraded by hyaluronidase conjugates of trypsin and ribonuclease A were also synthesised. The latter was intended to develop the possibility of designing novel anti cancer conjugates. A higher molecular weight dextrin 47,200 g/mol, 26 mol succinoylation was shown to best mask 34 trypsin activity and reinstate 58 of the activity by addition of amylase. When a HA fraction molecular weight 130,000 g/mol was prepared by acid hydrolysis and conjugated to trypsin 4 w/w, trypsin activity was masked to 6 and immediately re-instated to 24 on addition of hyaluronidase. Similarly, the dextrin-MSH conjugate reduced melanin production to 11 of the control and only restored to 33 on addition of amylase. RNase A alone was not cytotoxic up to 1 mg/mL, whereas, the HA-RNase A conjugate 0.1 mg/mL RNase A equivalent was cytotoxic in B16F10 and CV-1 cells 72 h. This work provides proof of principle for the concept of using biodegradable polymers to mask and reinstate conjugated protein activity in the presence of the appropriate enzyme 'unmasking' trigger.
APA, Harvard, Vancouver, ISO, and other styles
8

Ferguson, Elaine Lesley. "Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents." Thesis, Cardiff University, 2008. http://orca.cf.ac.uk/55750/.

Full text
Abstract:
Increasingly sophisticated new treatments such as trastuzumab (Herceptin ) and Bevacizumab (Avastin ) have contributed to reduced mortality from breast cancer over recent years, nevertheless 40--60 % of those affected still die from metastatic disease. Thus there remains an urgent need for novel therapies for breast cancer. As PLA2 (crotoxin) has proven anticancer activity but its use is limited by non-specific toxicity, and polymer-drug and polymer-protein conjugates are finding growing use as anticancer agents, the aim of this thesis was to explore the potential of polymer-PLA2 conjugates as a new treatment for breast cancer. Polymer conjugation has previously been shown to reduce systemic toxicity of proteins, prolong their plasma half-life and promote tumour-specific targeting by the enhanced permeability and retention (EPR) effect. First, the synthesis and characterisation methods were optimised using trypsin as a model. After these studies highlighted dextrin as the best polymer for conjugation, dextrin-PLA2 (Apis mellifera venom) conjugates were prepared. Dextrin was chosen for conjugation as it can be used to mask protein activity in the protein masked-unmasked polymer therapy (PUMPT) concept. Such conjugates retained 36 % enzyme activity compared to free PLA2, and moreover, unmasking by a-amylase degradation of dextrin regenerated full enzyme activity. However, while free PLA2 was found to be very haemolytic, dextrin-PLA2 displayed no haemolytic activity, and unmasking by a-amylase degradation of dextrin did not reinstate this activity. The conjugate displayed significant toxicity towards several tumour cell lines, including human breast cancer. Indirect evidence that epidermal growth factor receptor (EGFR) status and tyrosine kinase activity of the receptor influences PLA2-induced anti-proliferative activity were shown. Uptake studies have revealed that conjugation of dextrin to PLA2 reduces non-specific binding to breast cancer cells. In a further study, dextrin-PLA2's ability to burst DaunoXome using the polymer-enzyme liposome therapy (PELT) concept was assessed. Here, it was seen that the conjugate released liposomally encapsulated drug and the combination caused enhanced cytotoxicity in MCF-7 cells. These studies confirm the potential of dextrin-PLA2 as a novel anticancer agent and/or as trigger for liposomal drug release and highlight the feasibility of developing a candidate for further in vivo pharmacokinetic and activity studies.
APA, Harvard, Vancouver, ISO, and other styles
9

Mehta, Ankit N. "Tampon-like Foam Structures for Bioresponsive Vaginal Drug Delivery Applications." University of Cincinnati / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1396522494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bonner, Daniel Kenneth. "Understanding barriers to efficient nucleic acid delivery with bioresponsive block copolymers." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/70811.

Full text
Abstract:
Thesis (Ph. D.)--Harvard-MIT Program in Health Sciences and Technology, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references.
The delivery of nucleic acids has the potential to revolutionize medicine by allowing previously untreatable diseases to be clinically addressed. Viral delivery systems have been held back by immunogenicity and toxicity concerns, but synthetic vectors have lagged in transfection efficiency. This thesis describes the rational design and systematic study of three classes of bioresponsive polymers for nucleic acid delivery. A central theme of the study was understanding how the structure of the polymers impacted each of the intracellular steps of delivery, rather than solely the end result. A powerful tool for efficiently quantifying endosomal escape was developed and applied to each of the material systems described. First, a linear-dendritic poly(amido amine) -poly(ethylene glycol) (PAMAM-PEG) block copolymer system previously developed in our lab was evaluated and its ability to overcome the sequential barriers of uptake, endosomal escape, and nuclear import were characterized. Next, a class of crosslinked linear polyethyleimine (xLPEI) hyperbranched polymers, which can contain disulfideresponsive linkages, were synthesized and investigated. It was demonstrated that free polymer in solution, not the presence of a functional bioresponsive domain, was responsible for the highly efficient and relatively nontoxic DNA delivery of this promising class of crosslinked polyamines. Finally, this analysis was applied to siRNA delivery by a library of amine-functionalized synthetic polypeptides. The pH-responsive secondary structure, micelle formation, and ester hydrolysis were studied prior to the discrete barrier-oriented analysis of the siRNA delivery potential of this library. It is hoped that the tools, materials, and systemic analysis of structure-function relationships in this thesis will enhance the process of discovery and development of clinically relevant gene carriers.
by Daniel Kenneth Bonner.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bioresponsive"

1

Santin, Matteo, and Gary Phillips, eds. Biomimetic, Bioresponsive, and Bioactive Materials. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118129906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Biomimetic, bioresponsive, and bioactive materials: An introduction to integrating materials with tissues. Hoboken, NJ: Wiley, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hock, Bertold, ed. Bioresponse-Linked Instrumental Analysis. Wiesbaden: Vieweg+Teubner Verlag, 2001. http://dx.doi.org/10.1007/978-3-322-86568-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Deepa H. Bioresponsive Polymers. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Patel, Deepa H. Bioresponsive Polymers: Design and Application in Drug Delivery. Apple Academic Press, Incorporated, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Patel, Deepa H. Bioresponsive Polymers: Design and Application in Drug Delivery. Apple Academic Press, Incorporated, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Patel, Deepa H. Bioresponsive Polymers: Design and Application in Drug Delivery. Apple Academic Press, Incorporated, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patel, Deepa H. Bioresponsive Polymers: Design and Application in Drug Delivery. Apple Academic Press, Incorporated, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Santin, Matteo, and Gary J. Phillips. Biomimetic, Bioresponsive, and Bioactive Materials: An Introduction to Integrating Materials with Tissues. Wiley & Sons, Incorporated, John, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santin, Matteo, and Gary J. Phillips. Biomimetic, Bioresponsive, and Bioactive Materials: An Introduction to Integrating Materials with Tissues. Wiley & Sons, Incorporated, John, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bioresponsive"

1

Pathak, Drashti, and Deepa H. Patel. "Bioresponsive Nanoparticles." In Bioresponsive Polymers, 173–95. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patel, Deepa H., Drashti Pathak, and Neelang Trivedi. "Introduction to Bioresponsive Polymers." In Bioresponsive Polymers, 1–40. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Anita, Jayvadan K. Patel, and Deepa H. Patel. "Design of Bioresponsive Polymers." In Bioresponsive Polymers, 41–71. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lalan, Manisha, Deepti Jani, Pratiksha Trivedi, and Deepa H. Patel. "Application of Bioresponsive Polymers in Drug Delivery." In Bioresponsive Polymers, 73–119. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

William, Tamgue Serges, Drashti Pathak, and Deepa H. Patel. "Application of Bioresponsive Polymers in Gene Delivery." In Bioresponsive Polymers, 121–50. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pathak, Drashti, and Deepa H. Patel. "Recent Developments in Bioresponsive Drug Delivery Systems." In Bioresponsive Polymers, 151–72. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

William, Tamgue Serges, Dipali Talele, and Deepa H. Patel. "Bioresponsive Hydrogels for Controlled Drug Delivery." In Bioresponsive Polymers, 197–232. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429325243-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Xue, and Michael J. Serpe. "Bioresponsive Hydrogels and Microgels." In Chemistry of Bioconjugates, 370–86. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118775882.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Savii, Cecilia, and Ana-Maria Putz. "Recent Advances in Bioresponsive Nanomaterials." In Carbon Bonding and Structures, 379–435. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-1733-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santin, Matteo, and Gary Phillips. "History of Biomimetic, Bioactive and Bioresponsive Biomaterials." In Biomimetic, Bioresponsive, and Bioactive Materials, 1–34. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118129906.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bioresponsive"

1

"BIORESPONSE TO STEREOSCOPIC MOVIES PRESENTED VIA A HEAD-MOUNTED DISPLAY." In International Conference on Bio-inspired Systems and Signal Processing. SciTePress - Science and and Technology Publications, 2011. http://dx.doi.org/10.5220/0003155104330437.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Bioresponsive"

1

Hamilton, Mark F., Sarah L. Gourlie, and Paul A. Waters. Human Bioresponse to Low-Frequency Underwater Sound. Fort Belvoir, VA: Defense Technical Information Center, February 2009. http://dx.doi.org/10.21236/ada494255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bioresponsive' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography